BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 26005000)

  • 1. The multiple myeloma bone eco-system and its relation to oncogenesis.
    Bataille R
    Morphologie; 2015 Jun; 99(325):31-7. PubMed ID: 26005000
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biological aspects of altered bone remodeling in multiple myeloma and possibilities of pharmacological intervention.
    Kupisiewicz K
    Dan Med Bull; 2011 May; 58(5):B4277. PubMed ID: 21535989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Mechanisms for formation of myeloma bone disease].
    Yata K; Abe M; Matsumoto T
    Clin Calcium; 2008 Apr; 18(4):438-46. PubMed ID: 18379024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The critical role of interleukin-6, interleukin-1B and macrophage colony-stimulating factor in the pathogenesis of bone lesions in multiple myeloma.
    Bataille R; Chappard D; Klein B
    Int J Clin Lab Res; 1992; 21(4):283-7. PubMed ID: 1591381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Update on the pathogenesis of osteolysis in multiple myeloma patients.
    Giuliani N; Colla S; Rizzoli V
    Acta Biomed; 2004 Dec; 75(3):143-52. PubMed ID: 15796087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathogenesis of myeloma bone disease.
    Roodman GD
    J Cell Biochem; 2010 Feb; 109(2):283-91. PubMed ID: 20014067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of bortezomib on bone disease in patients with multiple myeloma.
    Mohty M; Malard F; Mohty B; Savani B; Moreau P; Terpos E
    Cancer; 2014 Mar; 120(5):618-23. PubMed ID: 24249482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathogenesis of myeloma bone disease.
    Roodman GD
    Leukemia; 2009 Mar; 23(3):435-41. PubMed ID: 19039321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathophysiology of multiple myeloma bone disease.
    Lentzsch S; Ehrlich LA; Roodman GD
    Hematol Oncol Clin North Am; 2007 Dec; 21(6):1035-49, viii. PubMed ID: 17996587
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Cytokines in bone diseases. Cytokines and myeloma bone disease].
    Abe M
    Clin Calcium; 2010 Oct; 20(10):1474-80. PubMed ID: 20890028
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor-host cell interactions in the bone disease of myeloma.
    Fowler JA; Edwards CM; Croucher PI
    Bone; 2011 Jan; 48(1):121-8. PubMed ID: 20615487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence for the secretion of an osteoclast stimulating factor in myeloma.
    Mundy GR; Raisz LG; Cooper RA; Schechter GP; Salmon SE
    N Engl J Med; 1974 Nov; 291(20):1041-6. PubMed ID: 4413338
    [No Abstract]   [Full Text] [Related]  

  • 13. Mechanisms of bone lesions in multiple myeloma.
    Bataille R; Chappard D; Klein B
    Hematol Oncol Clin North Am; 1992 Apr; 6(2):285-95. PubMed ID: 1582975
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects.
    Hurchla MA; Garcia-Gomez A; Hornick MC; Ocio EM; Li A; Blanco JF; Collins L; Kirk CJ; Piwnica-Worms D; Vij R; Tomasson MH; Pandiella A; San Miguel JF; Garayoa M; Weilbaecher KN
    Leukemia; 2013 Feb; 27(2):430-40. PubMed ID: 22763387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathogenesis of myeloma bone disease.
    Roodman GD
    Blood Cells Mol Dis; 2004; 32(2):290-2. PubMed ID: 15003820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myeloma cell-induced disruption of bone remodelling compartments leads to osteolytic lesions and generation of osteoclast-myeloma hybrid cells.
    Andersen TL; Søe K; Sondergaard TE; Plesner T; Delaisse JM
    Br J Haematol; 2010 Feb; 148(4):551-61. PubMed ID: 19919653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Bone disease in multiple myeloma and its mechanism].
    Abe M
    Clin Calcium; 2006 Apr; 16(4):565- 71. PubMed ID: 16582506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma.
    Bataille R; Chappard D; Marcelli C; Dessauw P; Baldet P; Sany J; Alexandre C
    J Clin Invest; 1991 Jul; 88(1):62-6. PubMed ID: 2056131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exosomes play a role in multiple myeloma bone disease and tumor development by targeting osteoclasts and osteoblasts.
    Faict S; Muller J; De Veirman K; De Bruyne E; Maes K; Vrancken L; Heusschen R; De Raeve H; Schots R; Vanderkerken K; Caers J; Menu E
    Blood Cancer J; 2018 Nov; 8(11):105. PubMed ID: 30409995
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myeloma impairs mature osteoblast function but causes early expansion of osteo-progenitors: temporal changes in bone physiology and gene expression in the KMS12BM model.
    Kassen D; Lath D; Lach A; Evans H; Chantry A; Rabin N; Croucher P; Yong KL
    Br J Haematol; 2016 Jan; 172(1):64-79. PubMed ID: 26767468
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.